The authors present a framework for the selection of immune aging biomarkers suitable for clinical trials in geroscience, alongside a translational roadmap for biomarker development to support the next generation of clinical studies on immune aging.
1 Comment so far
I appreciate that they didn’t just list out existing biomarkers—they actually built a whole selection framework specifically for clinical trials. That’s the kind of practical work this field has been missing for a while.
I appreciate that they didn’t just list out existing biomarkers—they actually built a whole selection framework specifically for clinical trials. That’s the kind of practical work this field has been missing for a while.